Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261
info@inspirna.com

Raymond Camahort

Ray is a Partner at Novo Ventures

Ray joined Novo Ventures in 2015 and has over 15 years of combined research, business development, and venture capital experience. Ray has served as a Board Observer at Checkmate Pharmaceuticals, Arcellx, Stride Bio, and Inspirna. Prior to joining Novo Ventures, Ray worked in business development at the Harvard University Office of Technology Development where he focused on licensing technologies developed in the Departments of Chemistry and Stem Cells and Regenerative Biology. Ray completed a National Institute of Health (NIH) post-doctoral training fellowship at Harvard University while concurrently holding a business development role at Partners Healthcare Research Ventures and Licensing. Ray was a pre-doctoral fellow at the Stowers Institute for Medical Research in Kansas City, Missouri, and he holds a PhD from the University of Kansas in biochemistry and molecular biology, and a BS in biological sciences from the University of California, Santa Barbara.